DORYX Drug Patent Profile

When do Doryx patents expire, and when can generic versions of Doryx launch?

Doryx is a drug marketed by Mayne Pharma and Warner Chilcott and is included in three NDAs. There are four patents protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in DORYX is doxycycline hyclate. There are twenty-eight drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the doxycycline hyclate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Doryx

A generic version of DORYX was approved as doxycycline hyclate by STRIDES PHARMA on March 29^th, 1982.

Summary for DORYX

International Patents:	2
US Patents:	1
Applicants:	2
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	57
Patent Applications:	2,608
Drug Prices:	Drug price information for DORYX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DORYX
What excipients (inactive ingredients) are in DORYX?	DORYX excipients list
DailyMed Link:	DORYX at DailyMed

See drug prices for DORYX

See drug sales revenues for DORYX

US Patents and Regulatory Information for DORYX

DORYX is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mayne Pharma	DORYX	doxycycline hyclate	CAPSULE, DELAYED RELEASE;ORAL	050582-002	Aug 13, 2001		DISCN	Yes	No
Mayne Pharma	DORYX	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	050795-002	May 6, 2005		DISCN	Yes	No			Y
Mayne Pharma	DORYX	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	050795-006	Dec 19, 2014		DISCN	Yes	No			Y
Mayne Pharma	DORYX MPC	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	050795-007	May 20, 2016		RX	Yes	No			Y
Mayne Pharma	DORYX	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	050795-003	Jun 20, 2008		DISCN	Yes	No			Y

Expired US Patents for DORYX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mayne Pharma	DORYX	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	050795-004	Apr 11, 2013
Mayne Pharma	DORYX	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	050795-006	Dec 19, 2014
Mayne Pharma	DORYX	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	050795-005	Apr 11, 2013
Mayne Pharma	DORYX	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	050795-002	May 6, 2005
Mayne Pharma	DORYX	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	050795-001	May 6, 2005

International Patents for DORYX

See the table below for patents covering DORYX around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2006045152
Australia	2005299253	Improved tabletting process

DORYX Market Analysis and Financial Projection

Last updated: April 24, 2026

Market dynamics and financial trajectory for DORYX

Doryx (doxycycline delayed-release tablets; marketed in several strengths and pack formats) tracks a mature, largely off-patent antibiotic landscape where pricing power is limited, procurement is payer-driven, and share shifts often hinge on supply continuity, contracting, and generic penetration rather than new clinical differentiation. Financial performance is typically shaped by: (1) generic entry and erosion of branded pricing, (2) payer and channel mix across commercial, government, and institutional buyers, (3) product availability and manufacturing throughput, and (4) competitive positioning against other tetracyclines and alternative antibiotic regimens.

This profile summarizes the market and financial drivers using an evidence-based framework centered on what is knowable from public patent/labeling and typical antibiotic commercialization patterns.

---

What market dynamics define Doryx performance?

1) Antibiotic category economics: limited long-run pricing power

Doxycycline is a standard-of-care antibiotic across multiple indications (label-dependent), and the competitive set is dominated by generics and therapeutically interchangeable doxycycline formulations. In this structure:

• Brand premiums compress quickly after generic entry.
• Net sales are more sensitive to contracting outcomes (rebates, formulary tiering) than to clinical demand growth.
• Substitution risk is high across the same active ingredient and dose form class.

For Doryx specifically, the “delayed-release” positioning reduces direct substitutability with immediate-release doxycycline, but it does not prevent generic competition.

2) Procurement and channel dynamics dominate

Performance for mature antibiotics usually depends on:

• Institutional contracting (group purchasing, pharmacy benefit manager negotiations)
• Government program mix (Medicare Part D and Medicaid formularies)
• Specialty distribution and hospital purchasing for specific strengths and pack sizes

The net effect is that sales growth rarely comes from pure consumption expansion; it comes from winning shelf space through pricing and reliable supply.

3) Supply continuity is a recurring determinant

Even when demand is stable, net sales can move with manufacturing disruptions or packaging availability. Doryx’s ability to maintain fill rates and deliver contracted volumes can influence:

• rebate outcomes
• wholesaler pull-through
• payer switching behavior after stockouts

4) Formulation and “delayed-release” differentiation

Doryx’s delayed-release mechanism is intended to improve gastrointestinal tolerability relative to standard formulations (label-driven). In practice, this affects market dynamics in two ways:

• It can reduce discontinuation versus immediate-release doxycycline for some patients.
• It can sustain a minimum level of brand or authorized-generic demand even after generic competition.

That said, “delayed-release” does not eliminate competition from other doxycycline products with acceptable tolerability profiles, and it does not stop payer substitution.

---

How does Doryx’s competitive landscape shape share and pricing?

Doxycycline’s competitive set is structured around:

• Other doxycycline oral products (immediate and delayed release)
• Other tetracyclines (therapeutic alternatives, substitution depending on indication and formularies)
• Non-tetracycline antibiotic regimens (clinical pathway dependent)

Key implications for Doryx commercialization:

• Brand-to-generic spread narrows as authorized generics and multiple generic manufacturers gain coverage.
• Formulary tiering matters more than brand awareness after initial brand cycles.
• Price elasticity is high because clinicians can adjust regimen type without long clinical switching barriers for many indications.

---

What financial trajectory should be expected for Doryx?

A base-case financial path for mature branded antibiotics

For products like Doryx once brand demand is challenged by generic penetration, the financial trajectory typically follows this sequence:

1. Early decline / normalization period post-generic entry

   • branded share shifts to authorized generics and low-cost alternatives
   • net price and volume both compress

2. Long-run stabilization at lower growth or near-flat volume

   • demand becomes stable because doxycycline use is protocolized
   • sales depend on contracting wins and supply

3. Ongoing margin pressure from rebate escalations and competitive bidding

   • even if volumes hold, net sales can decline in real terms due to pricing resets

What to watch for in Doryx-specific reporting

When investors or operators track Doryx financials, the most decision-relevant line items and signals are:

• Gross-to-net compression from rebates and payer concessions
• Channel mix changes (retail versus institutional; Medicare/Medicaid share)
• Pack and strength mix (higher-cost vs competitive price points)
• Inventory and supply events (sales volatility around disruptions)

---

What external forces could move Doryx net sales up or down?

1) Policy and reimbursement

• Formulary changes by PBMs and plan sponsors can change Doryx placement quickly.
• Government pricing pressure and contracting dynamics can reduce net selling price.

2) Competitive supply and manufacturer actions

• Launches by additional generic manufacturers can intensify bid pressure.
• Any sustained shortages can temporarily lift realized pricing and protect volume, then reverse after normalization.

3) Antimicrobial stewardship and prescribing patterns

Stewardship efforts can reduce broad antibiotic use, but doxycycline demand remains tied to common clinical indications and patient-specific needs. The result is usually demand stability with periodic shifts, not category collapse.

---

How do patents and regulatory life cycle elements affect the financial window?

Doryx is not positioned as a long-horizon patent-driven franchise in the way novel drugs are. For established doxycycline products, financial upside largely depends on:

• whether the specific dosage form and formulation retains enforceable exclusivity,
• whether switching is constrained by formulation-specific tolerability or patient response,
• whether generic access is delayed by regulatory or patent barriers.

When exclusivity ends, authorized generics and competing generics typically drive price resets.

---

What is the actionable market view for investors and R&D decision-makers?

1) Commercial thesis

• Doryx’s market is mature and contracting-driven.
• The most durable value levers are supply reliability and contract retention, not differentiated innovation.

2) Competitive strategy

For a brand or authorized branded supply, the practical strategy is:

• defend formulary placement at the contract level
• maintain manufacturing throughput
• manage inventory to avoid stockout-driven switching

3) R&D strategy

If considering future lifecycle extensions, success typically depends on:

• incremental formulation advantages that reduce switching
• improved adherence or tolerability that changes substitution behavior
• defensible regulatory exclusivity windows tied to the specific dosage form

---

Key Takeaways

• Doryx operates in a mature doxycycline antibiotic market where generic competition and contracting dominate net sales.
• Long-run financial performance tends to stabilize at lower pricing with volume tied to formulary access and supply continuity.
• The biggest short-cycle drivers are PBM/institutional contracting outcomes, rebate intensity, and manufacturing/supply events rather than clinical expansion.
• Future financial lift is most realistic through channel defense and lifecycle formulation advantages that reduce substitution.

---

FAQs

1) Is Doryx growth likely to come from new patient demand?

No. For mature doxycycline products, growth usually comes from winning contracts and maintaining share rather than expanding the underlying patient pool.

2) What most affects Doryx net price?

Net price is driven by rebates, formulary tiering, and bid/contract resets as generics intensify.

3) Does “delayed-release” protect Doryx from generic substitution?

It can reduce switching versus immediate-release in some cases, but it does not fully prevent substitution to doxycycline equivalents that meet payer and buyer needs.

4) What events typically cause quarterly volatility in products like Doryx?

Quarterly movement often tracks supply continuity, inventory and fill rates, and contract timing rather than demand shocks.

5) What is the most decision-relevant metric for tracking Doryx trajectory?

Track gross-to-net and channel mix (commercial vs institutional and government mix) alongside realized sales by strength/pack to understand whether volume is holding and whether pricing is stabilizing.

---

References

[1] U.S. Food and Drug Administration. Doryx (doxycycline delayed-release) labeling and product information. FDA Labeling. https://www.accessdata.fda.gov/ (accessed 2026-04-25)